Drugs aimed at mTOR (everolimus, metformin), AKT (MK2206), PI3K (buparlisib, rigosertib) are undergoing phase1-3 clinical trials in advanced pancreatic cancer patients (Wolpin et al., 2009; Ma et al., 2012; Bedard et al., 2015; Chung et al., 2017). The gene discussed is AKT1; the disease is familial pancreatic carcinoma.